Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Vienna Insurance Group (21/11/2023)

26.11.2023

Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters of 2023 (Q1-Q3 2022: € 7.1 million) due to the continued demand for Carragelose virus blockers. The increase in personnel costs, higher R&D expenses and lower research subsidies were reflected in the operating result of € -4.4 million (Q1-Q3 2022: € -3.8 million). The result for the period amounted to € -5.6 million, compared to € -5.8 million in the prior-year period. For the Carragelose platform, Marinomed took the necessary steps to create an all-year product portfolio and a product expansion in the therapeutic area of immunology with an allergy blocker and eye drops. The first market launches are already in preparation for 2024. Procter & Gamble also secured the rights for the Carragelose-based allergy spray in the USA. Marinomed has paved the way for further important partnerships for the product candidates Budesolv and Tacrosolv, which are based on the Marinosolv technology. In addition, licensing discussions were intensified at the trade fairs CPHI Barcelona, BIO-EUROPE Munich and the Jefferies London Healthcare Conference.
Marinomed Biotech: weekly performance: -11.79%

VIG: Vienna Insurance Group (VIG) has signed a purchase agreement to acquire 35% of the Hungarian holding company VIG Magyarország Befektetesi Zrt., which is currently held by the Hungarian state holding company Corvinus. After the transaction is completed, VIG’s stake in the Holding will increase from 55 to 90%, Corvinus will keep a stake of 10%. The parties have agreed not to disclose the purchase price.
VIG: weekly performance: 0.38%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/11/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Vienna Insurance Group (21/11/2023)


26.11.2023, 1723 Zeichen



Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters of 2023 (Q1-Q3 2022: € 7.1 million) due to the continued demand for Carragelose virus blockers. The increase in personnel costs, higher R&D expenses and lower research subsidies were reflected in the operating result of € -4.4 million (Q1-Q3 2022: € -3.8 million). The result for the period amounted to € -5.6 million, compared to € -5.8 million in the prior-year period. For the Carragelose platform, Marinomed took the necessary steps to create an all-year product portfolio and a product expansion in the therapeutic area of immunology with an allergy blocker and eye drops. The first market launches are already in preparation for 2024. Procter & Gamble also secured the rights for the Carragelose-based allergy spray in the USA. Marinomed has paved the way for further important partnerships for the product candidates Budesolv and Tacrosolv, which are based on the Marinosolv technology. In addition, licensing discussions were intensified at the trade fairs CPHI Barcelona, BIO-EUROPE Munich and the Jefferies London Healthcare Conference.
Marinomed Biotech: weekly performance: -11.79%

VIG: Vienna Insurance Group (VIG) has signed a purchase agreement to acquire 35% of the Hungarian holding company VIG Magyarország Befektetesi Zrt., which is currently held by the Hungarian state holding company Corvinus. After the transaction is completed, VIG’s stake in the Holding will increase from 55 to 90%, Corvinus will keep a stake of 10%. The parties have agreed not to disclose the purchase price.
VIG: weekly performance: 0.38%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/11/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Mi. 21.2.24: Früher DAX-Ausflug, wann kommt Vola?; neuer Challenger für Zalando und Wiens ytd-Nr. 1 korrigiert




 

Bildnachweis

Aktien auf dem Radar:DO&CO, Rosenbauer, Polytec Group, Austriacard Holdings AG, Addiko Bank, SBO, Rosgix, Porr, Uniqa, VIG, CA Immo, Österreichische Post, AT&S, ams-Osram, Frequentis, Kostad, Marinomed Biotech, Warimpex, S Immo, SW Umwelttechnik, Oberbank AG Stamm, Strabag, Zumtobel, Flughafen Wien, Athos Immobilien, Agrana, Amag, Erste Group, EVN, Immofinanz, Telekom Austria.


Random Partner

Semperit
Die börsennotierte Semperit AG Holding ist eine international ausgerichtete Unternehmensgruppe, die mit ihren beiden Divisionen Semperit Industrial Applications und Semperit Engineered Applications Produkte aus Kautschuk entwickelt, produziert und in über 100 Ländern weltweit vertreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten